drugset / Trial / NCT00846430
Medical Treatment of "High-Risk" Neurofibromas
NaSingle-groupOpen-labelTreatment
Summary
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.
Timeline
- Start
- 2008-10
- Primary completion
- 2017-04
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | — |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | — | — |
| Subject | Temozolomide | Small molecule | — | — |
| Subject | Vincristine | Small molecule | — | — |